Papers/PMID:31190742
Effect of pravastatin treatment on circulating adiponectin: a meta-analysis of randomized controlled trials.
Drug design, development and therapy2019The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
pravastatin — increases serum adiponectin
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“By pooling the results of the nine included comparisons, our meta-analysis showed that pravastatin treatment was associated with a significant increased level of circulating adiponectin as compared with controls (WMD =0.63 µg/mL; 95% CI, 0.17–1.09 µg/mL; P=0.007; Figure 2A), with moderate heterogeneity among the included studies (P for Cochrane’s Q test =0.20, I =28%).”
Quoted verbatim from Effect of pravastatin treatment on circulating adiponectin: a meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- Eight randomized controlled trials (nine comparisons) of patients with various disease statuses (hyperlipidemia, type 2 diabetes, metabolic syndrome, coronary artery disease), pravastatin versus control; total adiponectin measured by ELISA or radioimmunoassay
Effect 0.63 mean difference, 95% CI 0.17 to 1.09
Effect of pravastatin treatment on circulating adiponectin: a meta-analysis of randomized controlled trials.2019PMID:31190742Permalink